Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincenza Conteduca

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Clinical Genitourinary Cancer|September 19, 2015
Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient ProgrammeFrancesca Maines, Orazio Caffo, Ugo De Giorgi, et al.
BJU International|July 4, 2014
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient ProgrammeOrazio Caffo, Ugo De Giorgi, Lucia Fratino, et al.
Frontiers in Oncology|October 14, 2022
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centersPaolo Di Lorenzo, Vincenza Conteduca, Emanuela Scarpi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2025
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate CancerNicole Brighi, Daniel Wetterskog, Osvaldas Vainauskas, et al.
European Urology|November 6, 2020
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based TreatmentVicenç Ruiz de Porras, Xieng C Wang, Luis Palomero, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2024
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer careVincenza Conteduca, Piergiorgio Di Tullio, Rossana Allamprese, et al.
Science Translational Medicine|November 6, 2015
Plasma AR and abiraterone-resistant prostate cancerAlessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, et al.
The Oncologist|November 17, 2025
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysisFabrizio Di Costanzo, Chiara Mercinelli, Alessio Signori, et al.
The Oncologist|August 3, 2022
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO NetworkPasquale Rescigno, Marco Maruzzo, Sara Elena Rebuzzi, et al.
Science Translational Medicine|March 22, 2019
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancerLoredana Puca, Katie Gavyert, Verena Sailer, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Clinical Genitourinary Cancer|September 19, 2015
Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient ProgrammeFrancesca Maines, Orazio Caffo, Ugo De Giorgi, et al.
BJU International|July 4, 2014
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient ProgrammeOrazio Caffo, Ugo De Giorgi, Lucia Fratino, et al.
Frontiers in Oncology|October 14, 2022
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centersPaolo Di Lorenzo, Vincenza Conteduca, Emanuela Scarpi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2025
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate CancerNicole Brighi, Daniel Wetterskog, Osvaldas Vainauskas, et al.
European Urology|November 6, 2020
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based TreatmentVicenç Ruiz de Porras, Xieng C Wang, Luis Palomero, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2024
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer careVincenza Conteduca, Piergiorgio Di Tullio, Rossana Allamprese, et al.
Science Translational Medicine|November 6, 2015
Plasma AR and abiraterone-resistant prostate cancerAlessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, et al.
The Oncologist|November 17, 2025
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysisFabrizio Di Costanzo, Chiara Mercinelli, Alessio Signori, et al.
The Oncologist|August 3, 2022
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO NetworkPasquale Rescigno, Marco Maruzzo, Sara Elena Rebuzzi, et al.
Science Translational Medicine|March 22, 2019
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancerLoredana Puca, Katie Gavyert, Verena Sailer, et al.
Pageof 16